THE EFFECTIVENESS OF LACTOBACILLUS CRISPATUS PROBIOTICS AS PROPHYLACTIC THERAPY FOR BACTERIAL VAGINOSIS RECURRENCE: A SYSTEMATIC REVIEW AND META-ANALYSIS

The Effectiveness of Lactobacillus crispatus Probiotics as Prophylactic Therapy for Bacterial Vaginosis Recurrence: A Systematic Review and Meta-analysis

Irvin Aldikha¹*, Puguh Riyanto¹, Asih Budiastuti¹, Diah Adriani Malik¹, Retno Indar Widayati¹, Muslimin¹, Hardian²

¹Departement of Dermatovenereology, Faculty of Medicine, Diponegoro University/ Dr. Kariadi General Hospital Medical Center, Jl. Dr. Sutomo No. 16, 50244, Semarang, Indonesia.²Departement of Physiology, Faculty of Medicine, Diponegoro University, Jl. Prof. Soedarto, Tembalang, 50275, Semarang, Indonesia

Background: Bacterial vaginosis (BV) is one the main causes of fluor albus in women which is found in 15 – 50% of all reproductive age in the world. Regimen therapy for bacterial vaginosis consists of antibiotics, but the recurrence rates remain high. Probiotics appear to have an effect on treating or preventing bacterial vaginosis recurrence. One of the probiotics is Lactobacillus crispatus.

Methods: The result of online searching on Pubmed-MEDLINE, Scopus, EBSCOhost, Cambridge Core, ProQuest, Cochrane library, ClinicalTrials.gov, and Google Scholar databases had found 4 relevant articles included in this systematic review (n = 516 subjects), from which 3 articles were used in meta-analysis (n = 350 subjects).

Results: The meta-analysis of effectiveness of L. crispatus probiotics intervention group compared to the placebo group showed a homogeneity in data (Q=2.170, df=2; p=0.338, Tau2=0.026). Meta-analysis showed the value of Q statistic was z value = -2.683; (p=0.007) and overall risk ratio is 0.694 (95% CI= 0.532 to 0.906) with p=0.007. This demonstrated that the group with L. crispatus probiotics had 0.694 times lower risk in having bacterial vaginosis recurrence compared to the placebo group. The test for overall effect found the time to recurrence of placebo group was shorter compared to probiotics group with overall mean time to recurrence between probiotics group and placebo group was -0.960±0.20 (Z value= -4.730; p<0.001). Systematic review showed the administration of probiotic L. crispatus prevented recurrence and prolonged the occurence of BV recurrence with a good safety profile.

Conclusion: Systematic review and meta-analysis results show that Lactobacillus crispatus probiotics administration after antibiotics therapy can significantly lower the incidence of bacterial vaginosis recurrence and prolong the time to recurrence.

Keywords: bacterial vaginosis, probiotics, Lactobacillus crispatus

Free Full-text PDF

How to cite this article:

Irvin Aldikha, Puguh Riyanto, Asih Budiastuti, Diah Adriani Malik, Retno Indar Widayati, Muslimin, and Hardian. The Effectiveness of Lactobacillus crispatus Probiotics as Prophylactic Therapy for Bacterial Vaginosis Recurrence: Systematic Review and Meta-analysis .American Journal of Dermatological Research and Reviews, 2022, 5:54. DOI: 10.28933/ajodrr-2022-06-0505ia

References:

1. Rostok M, Hutt P, Roop T, Smidt I, Stsepetova J, Salumets A,et al. Potential vaginal probiotics: safety, tolerability and preliminary effectiveness. Benef Microbes. 2019;10(4):385-93.
2. Cohen CR, Wierzbicki MR, French AL, Morris S, Newmann S, Reno H, et al. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med. 2020;382:1906-15.
3. van de Wijgert JH, Jespers V. The global health impact of vaginal dysbiosis. Res microbiol. 2017;168(9-10):859-64.
4. Joesoef MR, Karundeng A, Runtupalit C, Moran JS, Lewis JS, Ryan CA. High rate of bacterial vaginosis among women with intrauterine devices in Manado, Indonesia. Contraception. 2001;64:169-72.
5. Bohbot JM, Darai E, Bretelle F, Brami G, Daniel C, Cardot JM. Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence. J Gynecol Obstet Hum Reprod. 2018;47(2):81-6.
6. Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Centers for Disease Control and Prevention. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187.
7. Reiter S, Spadt SK. Bacterial vaginosis: a primer for clinicians. Postgrad Med. 2019;131(1):8-18.
8. Xiao B, Wu C, Song W, Niu X, Qin N, Liu Z, et al. Association Analysis on Recurrence of Bacterial Vaginosis Revealed Microbes and Clinical Variables Important for Treatment Outcome. Front Cell Infect Microbiol. 2019;9(189):1-11.
9. Bastani P, Homayouni A. Dairy probiotics foods and bacterial vaginosis: a review on mechanism of action. INTECH. 2012;20:445-57.
10. Foschi C, Salvo M, Cevenini R, Parolin C, Vitali B, Marangoni A. Vaginal Lactobacilli Reduce Neisseria gonorrhoeae Viability through Multiple Strategies: An in Vitro Study. Front Cell Infect Microbiol. 2017;7(502):1-10.
11. Mohammed L, Javed M, Althwanay A, Ahsan F, Oliveri F, Goud HK, et al. Live Bacteria Supplementation as Probiotic for Managing Fishy, Odorous Vaginal Discharge Disease of Bacterial Vaginosis: An Alternative Treatment Option?. Cureus. 2020;12(12):1-8.
12. Joseph RJ, Ser HL, Kuai YH, Tan LT, Arasoo VJ, Letchumanan V, et al. Finding a Balance in the Vaginal Microbiome: How Do We Treat and Prevent the Occurence of Bacterial Vaginosis?. Antibiotics. 2021;10(6):1-39.
13. Almeida MO, do Carmo FL, Gala-Garcia A, Kato R, Gomide AC, Drummond RM, et al. Lactobacillus crispatus protects against bacterial vaginosis. Genet Mol Res. 2019;18(4):1-22.
14. Reznichenko H, Henyk N, Maliuk V, Khyzhnyak T, Tynna Y, Filipiuk I, et al. Oral Intake of Lactobacilli Can Be Helpful in Symptomatic Bacterial Vaginosis: A Randomized Clinical Study. J Low Genit Tract Dis. 2020;24(3):284-9.
15. Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sex transm dis. 2010;37(12):745-50.
16. Sobel JD. Bacterial vaginosis: treatment [Internet]. 2022 [cited 2022 May 7]. Available from: https://www.uptodate.com/contents/bacterial-vaginosis treatment.
17. Abdelmaksoud AA, Koparde VN, Sheth NU, Serrano MG, Glascock AL, Fettweis JM, et al. Comparison of Lactobacillus crispatus isolates from Lactobacillus-dominated vaginal microbiomes with isolates from microbiomes containing bacterial vaginosis-associated bacteria. Microbiology (reading). 2016;162(Pt 3):466-75.
18. Parma M, Vanni VS, Bertini M, Candiani M. Probiotics in the prevention of recurrences of bacterial vaginosis. Altern Ther Health Med. 2014;20(Suppl 1):52-7.
19. Muzny CA, Sobel JD. The Role of Antimicrobial Resistance in Refractory and Recurrent Bacterial Vaginosis and Current Recommendations for Treatment. Antibiotics (Basel). 2022;11(4):1-12.
20. Wu S, Hugerth LW, Schuppe-Koistinen I, Du J. The right bug in the right place: opportunities for bacterial vaginosis treatment. NPJ Biofilms Microbiomes. 2022;8(1):1-11.